Utama › Kanser Ginjal › Florida
Kajian klinikal Kanser Ginjal di Florida
14 kajian untuk Kanser Ginjal sedang mencari peserta di lokasi di Florida.
Bandar di Florida
Teks kajian rasmi (Bahasa Inggeris)
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
- Research Site, Jacksonville
- Research Site, Miami
- Research Site, Orlando
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 29 Sep 2026 · NCT07011719Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
- Mayo Clinic Jacksonville, Jacksonville
- Moffitt Cancer Center, Tampa
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT04981119NSAID Use After Robotic Partial Nephrectomy
- University of Miami, Miami
Mengambil pesertaFasa 2
Umur 18 hingga 99 · Semua jantina · Dikemas kini 24 Sep 2026 · NCT05842044Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
- Mayo Clinic Pharmacy, Jacksonville
- Orlando Health Ambulatory Care Center, Orlando
- Orlando Health Cancer Institute, Orlando
- dan 1 lagi
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 17 Sep 2026 · NCT07227415A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
- Research Site, Miami
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 31 Ogo 2026 · NCT05536141Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
- Xencor Investigative Site, Jacksonville
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 3 Ogo 2026 · NCT05433142Integrated Cancer Repository for Cancer Research
- Florida Hospital Memorial Medical Center, Daytona Beach
- Florida Hospital DeLand, DeLand
- Florida Hospital FISH, Orange City
- dan 2 lagi
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Umur 19 hingga 110 · Semua jantina · Dikemas kini 29 Jun 2026 · NCT02012699KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
- AdventHealth Celebration, Celebration
- Mayo Clinic Comprehensive Cancer Center, Jacksonville
- Florida Cancer Specialists, Sarasota
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 8 Jun 2026 · NCT06026410Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
- Sylvester Comprehensive Cancer Center - University of Miami Health System, Miami
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 6 Mei 2026 · NCT06239194A Study of VET3-TGI in Patients With Solid Tumors
- University of Miami, Miami
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 7 Apr 2026 · NCT06444815cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- Miami Cancer Institute, Miami
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Umur 40 ke atas · Semua jantina · Dikemas kini 20 Jan 2026 · NCT05366881SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Jacksonville
- Massive Bio SYNERGY-AI site, Miami
- Massive Bio SYNERGY-AI site, Tampa
Mengambil pesertaKajian pemerhatian
Semua umur · Semua jantina · Dikemas kini 28 Okt 2025 · NCT03452774A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
- Mayo Clinic, Jacksonville
- Moffitt Cancer Center, Tampa
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 9 Sep 2025 · NCT06682793Cryaoablation Assisted Partial Nephrectomy a Non Ischemic Approach
- Urological Research Network, Miami Lakes
Mengambil peserta
Umur 55 hingga 65 · Semua jantina · Dikemas kini 26 Jan 2023 · NCT05218811Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.